Will M. Aklin, Ph.D., is director of the Behavioral Therapy Development Program (BTDP) within the Division of Therapeutics and Medical Consequences at NIDA. The overarching goal of BTDP is to produce efficacious, implementable and self-sustaining treatments for substance use disorders. BTDP supports Stage I (treatment generation, refinement), Stage II (efficacy), and Stage III (efficacy in the real-world) research. Research areas supported by BTDP include development of treatments targeting specific novel or insufficiently-studied behavioral and neurobehavioral processes (e.g., impulsivity, risk-taking propensity, decision-making), the examination of theory-derived treatment targets and mechanisms of behavior change, adherence, and studies that integrate behavioral/pharmacological, technology- and neuromodulatory-based treatment. Dr. Aklin received his Ph.D. in Clinical Psychology from the University of Maryland. He completed his clinical residency at Yale University School of Medicine, and a post-doctoral fellowship at Johns Hopkins University School of Medicine—Behavioral Pharmacology Research Unit. He has received numerous awards and honors, including Early Career Investigator Awards from the College on Problem of Drug Dependence (CPDD) and the Association of Behavioral and Cognitive Therapies (ABCT). Dr. Aklin’s areas of research include the development of treatments targeting specific neurobehavioral processes (e.g., impulsivity, risk-taking, decision-making), the examination of theory-derived treatment targets and mechanisms of behavior change, adherence, and studies that integrate behavioral/pharmacological treatment. Dr. Aklin has extensive clinical research experience in behavioral and cognitive-behavioral treatment for substance dependence; adaptive brief interventions and adherence trials. He joined NIDA in 2008.